TWI801711B - Composition for restoring the skin barrier and use thereof - Google Patents
Composition for restoring the skin barrier and use thereof Download PDFInfo
- Publication number
- TWI801711B TWI801711B TW109103251A TW109103251A TWI801711B TW I801711 B TWI801711 B TW I801711B TW 109103251 A TW109103251 A TW 109103251A TW 109103251 A TW109103251 A TW 109103251A TW I801711 B TWI801711 B TW I801711B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- weight percentage
- ceramide
- skin
- ion
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本發明是有關於一種修復皮膚屏障組合物及其用途,且特別是有關於一種具有靈芝萃取物以及離子調節劑的修復皮膚屏障組合物及其用途。 The present invention relates to a composition for repairing skin barrier and its use, and in particular to a composition for repairing skin barrier with Ganoderma lucidum extract and ion regulator and its use.
皮膚為目前已知人體最大的器官,皮膚的重要性在於,將富含水分的內部器官與外在乾燥的環境隔離。皮膚具有屏障功能,屏障功能是由位於皮膚最上層的角質層(人類為約10微米至20微米)所提供,正常的皮膚屏障功能可防止外在刺激原入侵皮膚且皮膚水分不易散失。 The skin is the largest known organ in the human body. The importance of the skin is to isolate the moisture-rich internal organs from the external dry environment. The skin has a barrier function, and the barrier function is provided by the stratum corneum (approximately 10 microns to 20 microns for humans) located on the uppermost layer of the skin. The normal skin barrier function can prevent external stimuli from invading the skin and the skin moisture is not easy to lose.
角質層(stratum corneum)是皮膚表皮的最外層,主要由15層至20層沒有細胞核的死亡細胞組成。當這些細胞脫落時,底下位於基底層的細胞會被推擠上來,而形成新的角質層。角質層由兩種成分組成:富含蛋白質的非活性角質細胞以及由脂質所構成之細胞間基質。藉由角質細胞與脂質 的組合,形成特定之「磚與泥」結構,使得角質層呈現高度不透水的能力。 The stratum corneum is the outermost layer of the skin epidermis and consists mainly of 15 to 20 layers of dead cells without nuclei. When these cells are shed, the underlying cells in the basal layer are pushed up to form a new stratum corneum. The stratum corneum is composed of two components: protein-rich inactive keratinocytes and an intercellular matrix composed of lipids. Keratinocytes and lipids The combination of them forms a specific "brick and mud" structure, which makes the cuticle highly impermeable.
皮膚內的離子濃度在屏障的功能上,扮演著重要角色。鈣離子在細胞的訊息傳遞體系中,為重要的信使,多數的細胞具有接受鈣離子之特殊受體。在皮膚中,鈣離子可對細胞提供細胞內或細胞外信號。已發現細胞內鈣離子濃度隨著細胞外鈣離子濃度的提高而增加,細胞內鈣離子的增加為激發角質細胞分化之信號。在角質細胞中,細胞外含量與細胞內濃度通常維持平衡。此外,鈣離子參與角質細胞的分化,同時也有助於角質細胞分泌脂質。 The ion concentration in the skin plays an important role in the function of the barrier. Calcium ions are important messengers in the cell's message transmission system, and most cells have special receptors that accept calcium ions. In the skin, calcium ions can provide intracellular or extracellular signals to cells. It has been found that the concentration of intracellular calcium ions increases with the increase of the concentration of extracellular calcium ions, and the increase of intracellular calcium ions is a signal to stimulate keratinocyte differentiation. In keratinocytes, the extracellular content is normally in balance with the intracellular concentration. In addition, calcium ions participate in the differentiation of keratinocytes and also help keratinocytes secrete lipids.
正常皮膚中,鈣離子以高濃度侷限於角質層下方的表皮顆粒層中,且在表皮層存在鈣離子濃度梯度。上表皮之鈣離子含量高於下表皮,即自基底層區域至角質層之間穩定地增加,形成倒梯形濃度分布,其他離子則否。然而,當皮膚處在病理情況下,表皮層的鈣離子濃度分布情形會改變,即鈣離子的濃度梯度不再如同健康皮膚中呈倒梯形分布。 In normal skin, calcium ions are localized at high concentrations in the granular layer of the epidermis below the stratum corneum, and there is a concentration gradient of calcium ions in the epidermis. The calcium ion content of the upper epidermis is higher than that of the lower epidermis, that is, it increases steadily from the basal layer to the stratum corneum, forming an inverted trapezoidal concentration distribution, while other ions do not. However, when the skin is under pathological conditions, the concentration distribution of calcium ions in the epidermis will change, that is, the concentration gradient of calcium ions is no longer distributed in an inverted trapezoid as in healthy skin.
靈芝萃取物(Ganoderma Extract)可促進細胞再生,幫助傷口癒合。靈芝萃取物透過下列四種機制回復傷口:(1)靈芝萃取物能夠顯著促進纖維母細胞(fibroblast cells)以及角質細胞(keratinocyte)的增生,同時增加纖維母細胞遷移的能力,達到加速傷口癒合的功效;(2)靈芝萃取物能有效降低基質金屬蛋白酶(Matrix metalloproteinase)MMP-9的活性,降低傷 口周邊組織之細胞基質過度分解,進而達到幫助組織重建、縮短傷口發炎期的功效;(3)靈芝萃取物能有效抑制蛋白質分解酶(proteases)的活性,讓細菌因無法獲取養分而死亡;透過抑制肌膚表面細菌生長,達到天然抑制發炎的功效;(4)靈芝細胞壁萃取物主要由50-60%多醣體(polysaccharides)以及40-50%幾丁質(chitin)組成,此兩種成分為已知極佳的保濕活性,能夠提供傷口癒合所需之保濕環境,藉此加速傷口之修復。 Ganoderma Extract can promote cell regeneration and help wound healing. Ganoderma lucidum extract restores wounds through the following four mechanisms: (1) Ganoderma lucidum extract can significantly promote the proliferation of fibroblast cells and keratinocytes, and at the same time increase the ability of fibroblast cell migration to accelerate wound healing Efficacy; (2) Ganoderma lucidum extract can effectively reduce the activity of Matrix metalloproteinase MMP-9, reduce the excessive decomposition of cell matrix in the tissue around the wound, and then achieve the effect of helping tissue reconstruction and shortening the wound inflammation period; (3) Ganoderma lucidum extract can effectively inhibit the activity of proteases, causing bacteria to die due to lack of nutrients; by inhibiting the growth of bacteria on the skin surface, it can naturally inhibit inflammation; (4) Ganoderma lucidum cell wall extract is mainly composed of 50-60 % polysaccharides (polysaccharides) and 40-50% chitin (chitin), these two ingredients are known to have excellent moisturizing activity, which can provide the moisturizing environment required for wound healing, thereby accelerating wound repair.
然而,若單獨使用靈芝萃取物雖可促進皮膚角質細胞增生並恢復傷口癒合,但無法恢復健康皮膚中的鈣離子濃度梯度的倒梯形分布,導致皮膚屏障仍無法發揮正常功能。若外在刺激原侵入皮膚細胞時水分容易散失,且細胞受到刺激後容易產生發炎現象。 However, although Ganoderma lucidum extract alone can promote skin keratinocyte proliferation and restore wound healing, it cannot restore the inverted trapezoidal distribution of calcium ion concentration gradient in healthy skin, resulting in the failure of the skin barrier to function normally. If the external stimulus invades the skin cells, the water will be easily lost, and the cells will be prone to inflammation after being stimulated.
有鑑於此,如何發展出促進皮膚角質細胞增生的同時,並回復皮膚中的鈣離子濃度梯度的倒梯形的分布以修復皮膚屏障的組合物,現有技術實有待改善的必要。 In view of this, how to develop a composition that promotes the proliferation of skin keratinocytes and restores the inverted trapezoidal distribution of the calcium ion concentration gradient in the skin to repair the skin barrier, the prior art needs to be improved.
本發明的目的在於提供一種修復皮膚屏障的組合物,除了能促進皮膚角質細胞的增生外,並提供皮膚中適當的離子環境,以達成回復皮膚中的鈣離子濃度梯度的倒梯形分布而恢復皮膚屏障的功效。 The object of the present invention is to provide a composition for repairing the skin barrier, which can not only promote the proliferation of skin keratinocytes, but also provide an appropriate ion environment in the skin, so as to restore the inverted trapezoidal distribution of the calcium ion concentration gradient in the skin and restore the skin. The efficacy of the barrier.
本發明提供了一種修復皮膚屏障的組合物,包含:靈芝萃取物;以及離子調節劑,包含鈣離子、鎂離子、鈉 離子、鉀離子及氯離子,其中組合物的總重量以100%計,靈芝萃取物的重量百分比為0.0000072%至0.11%、鈣離子的重量百分比為0.0001244%至0.04998%、鎂離子的重量百分比為0.0000412%至0.03157%、鈉離子的重量百分比為0.0002133%至0.09114%、鉀離子的重量百分比為0.0000875%至0.03301%、及氯離子的重量百分比為0.0004754%至0.16639%。 The present invention provides a composition for repairing the skin barrier, comprising: Ganoderma lucidum extract; and an ion regulator, comprising calcium ions, magnesium ions, sodium ions, potassium ions and chloride ions, wherein the total weight of the composition is based on 100%, the weight percentage of Ganoderma lucidum extract is 0.0000072% to 0.11%, the weight percentage of calcium ions is 0.0001244% to 0.04998%, and the weight percentage of magnesium ions is 0.0000412% to 0.03157%, the weight percentage of sodium ions is 0.0002133% to 0.09114%, the weight percentage of potassium ions is 0.0000875% to 0.03301%, and the weight percentage of chloride ions is 0.0004754% to 0.16639%.
在一些實施方式中,靈芝萃取物包含葡聚糖和胺基葡萄糖的共聚物,葡聚糖包含α-葡聚糖、β-葡聚糖或其組合,胺基葡萄糖包含N-乙醯葡萄糖胺(N-Acetylglucosamine,GlcNAc)、N-乙醯胞壁酸(N-Acetylmuramic acid,MurNAc)或其組合。 In some embodiments, the Ganoderma lucidum extract comprises a copolymer of dextran comprising α-glucan, β-glucan or a combination thereof and glucosamine comprising N-acetylglucosamine ( N -Acetylglucosamine, GlcNAc), N-acetylmuramic acid (N-Acetylmuramic acid, MurNAc) or a combination thereof.
在一些實施方式中,靈芝萃取物包含微米等級的靈芝萃取物或奈米等級的靈芝萃取物,其中微米等級的靈芝萃取物的重量百分比為0.0000072%至0.088%,奈米等級的靈芝萃取物的重量百分比為0.00018%至0.11%。 In some embodiments, the Ganoderma lucidum extract comprises micron-scale Ganoderma lucidum extract or nano-scale Ganoderma lucidum extract, wherein the weight percentage of the micron-scale Ganoderma lucidum extract is 0.0000072% to 0.088%, and the weight percentage of the nano-scale Ganoderma lucidum extract is The weight percentage is 0.00018% to 0.11%.
在一些實施方式中,組合物更包含脂質,脂質的重量百分比為0.001%至40%。 In some embodiments, the composition further comprises lipid, and the weight percentage of lipid is 0.001% to 40%.
在一些實施方式中,組合物更包含脂質,脂質的重量百分比為0.001%至15%。 In some embodiments, the composition further comprises lipid, and the weight percentage of lipid is 0.001% to 15%.
在一些實施方式中,脂質包含神經醯胺、甘油酯、膽固醇、游離脂肪酸或其組合。 In some embodiments, the lipid comprises ceramides, glycerides, cholesterol, free fatty acids, or combinations thereof.
在一些實施方式中,神經醯胺包含神經醯胺1、神經醯胺2、神經醯胺3、神經醯胺4、神經醯胺5、神經醯胺6、神經醯胺7、神經醯胺8、神經醯胺9、或其組合。
In some embodiments, the ceramide comprises ceramide 1, ceramide 2, ceramide 3, ceramide 4,
在一些實施方式中,組合物係用於治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀,皮膚病包括異位性皮膚炎(atopic dermatitis)、脂漏性皮膚炎(seborrhoeic dermatitis)、接觸性皮膚炎(contact dermatitis)、紅斑性狼瘡(lupus erythematosus)、扁平苔癬(lichen planus)、蕁麻疹(urticaria)、角化病(keratosis)、痤瘡(acne)、牛皮癬(psoriasis)、或魚鱗病(ichthyosis)。 In some embodiments, the composition is used for treating skin diseases or improving skin discomfort or abnormal symptoms caused by diseases. Skin diseases include atopic dermatitis, seborrhoeic dermatitis, Contact dermatitis, lupus erythematosus, lichen planus, urticaria, keratosis, acne, psoriasis, or ichthyosis Disease (ichthyosis).
在一些實施方式中,組合物係呈液劑、精華液、洗劑、卸妝產品、面膜、擦拭產品、乳液、乳霜、軟膏、或凝膠之形式。其中,液劑可例如為化妝水。 In some embodiments, the composition is in the form of a lotion, serum, lotion, makeup remover, mask, wipe, lotion, cream, ointment, or gel. Wherein, the liquid formulation may be, for example, lotion.
在一些實施方式中,組合物更包含化妝品可接受的載劑。 In some embodiments, the composition further comprises a cosmetically acceptable carrier.
在一些實施方式中,化妝品可接受的載劑包含溶劑、潤膚劑、保濕劑、乳化劑、增稠劑、抗氧化劑、防腐劑或其組合。 In some embodiments, the cosmetically acceptable carrier comprises solvents, emollients, humectants, emulsifiers, thickeners, antioxidants, preservatives, or combinations thereof.
在一些實施方式中,潤膚劑的重量百分比為7%至22%;保濕劑的重量百分比為4%至12%;乳化劑的重量百分比為2%至6.5%;增稠劑的重量百分比為0.3%至1%;抗氧化劑的重量百分比為0.2%至0.8%;以及防腐劑的重量百分比為0.0004%至0.002%。 In some embodiments, the weight percentage of emollient is 7% to 22%; the weight percentage of humectant is 4% to 12%; the weight percentage of emulsifier is 2% to 6.5%; the weight percentage of thickener is 0.3% to 1%; antioxidants 0.2% to 0.8% by weight; and preservatives 0.0004% to 0.002% by weight.
在一些實施方式中,潤膚劑的重量百分比為2%至30%;保濕劑的重量百分比為0.1%至20%;乳化劑的重量百分比為0.1%至10%;增稠劑的重量百分比為0.1%至5%;抗氧化劑的重量百分比為0.01%至5%;以及防腐劑的重量百分比為0.0004%至5%。 In some embodiments, the weight percentage of emollient is 2% to 30%; the weight percentage of humectant is 0.1% to 20%; the weight percentage of emulsifier is 0.1% to 10%; the weight percentage of thickener is 0.1% to 5%; antioxidants 0.01% to 5% by weight; and preservatives 0.0004% to 5% by weight.
在一些實施方式中,組合物更包含藥學上可接受的載劑。 In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.
本發明另提供了一種組合物的用途,係用於製備治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀的製劑,其中組合物如前所述。 The present invention also provides the use of a composition for preparing preparations for treating skin diseases or improving skin discomfort or abnormal symptoms caused by diseases, wherein the composition is as described above.
在一些實施方式中,皮膚病包括異位性皮膚炎、脂漏性皮膚炎、接觸性皮膚炎、紅斑性狼瘡、扁平苔癬、蕁麻疹、角化病、痤瘡、牛皮癬、或魚鱗病。 In some embodiments, the skin disease comprises atopic dermatitis, seborrheic dermatitis, contact dermatitis, lupus erythematosus, lichen planus, urticaria, keratosis, acne, psoriasis, or ichthyosis.
本發明另提供了一種組合物的用途,係用於製備治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀的製劑,其中組合物如前所述,其中投與該組合物為每日至少一次。 The present invention also provides the use of a composition, which is used to prepare preparations for treating skin diseases or improving skin discomfort or abnormal symptoms caused by diseases, wherein the composition is as described above, wherein the composition is administered daily at least once.
在一些實施方式中,皮膚病或該疾病所引起之皮膚不適或異常症狀於施予該組合物兩天時,其恢復率相較於對照組增加10%或更多。 In some embodiments, the recovery rate of the skin disease or skin discomfort or abnormal symptoms caused by the disease is increased by 10% or more compared with the control group when the composition is administered for two days.
承上所述,本發明在組合物中,由組合物中之靈芝萃取物促進細胞再生,加速皮膚角質細胞增生。再利用離子調節劑中特定比例的離子組合,回復皮膚表皮層中的鈣離子濃度梯度的倒梯形分布,以提供適合角質細胞生長的 環境。最後,特定比例的離子組合可持續維持皮膚屏障層的鈣離子濃度梯度的倒梯形分布,維持新生皮膚屏障之功能。藉由本發明組合物修復皮膚屏障,可防止外在刺激原入侵皮膚及皮膚水分流失,避免皮膚受到外在刺激後導致發炎反應而有紅腫熱刺的不舒適感。其次,本發明組合物亦可用於病理狀態下的皮膚,藉由修復皮膚屏障而治療或改善皮膚不適或異常症狀,包含洗腎透析病患的皮膚搔癢症狀。 As mentioned above, in the composition of the present invention, the Ganoderma lucidum extract in the composition promotes cell regeneration and accelerates the proliferation of skin keratinocytes. Then use the ion combination in a specific ratio in the ion regulator to restore the inverted trapezoidal distribution of the calcium ion concentration gradient in the epidermal layer of the skin to provide a suitable environment for the growth of keratinocytes. environment. Finally, the combination of ions in a specific ratio can sustainably maintain the inverted trapezoidal distribution of the calcium ion concentration gradient of the skin barrier layer and maintain the function of the new skin barrier. Repairing the skin barrier by the composition of the present invention can prevent external stimuli from invading the skin and losing water in the skin, and prevent the skin from being irritated by external stimuli and causing discomfort such as redness, swelling, and heat. Secondly, the composition of the present invention can also be used on the skin under pathological conditions to treat or improve skin discomfort or abnormal symptoms by repairing the skin barrier, including skin itching symptoms of kidney dialysis patients.
為讓本發明之上述和其他目的、特徵、優點與實施例能更明顯易懂,所附圖式之說明如下: In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the accompanying drawings are described as follows:
第1圖繪示本揭示內容之一實施方式之各組第2天經皮水分散失量的柱狀圖。 Figure 1 shows a histogram of the transdermal water loss of each group on day 2 according to an embodiment of the present disclosure.
第2圖繪示本揭示內容之一實施方式之各組第2天恢復率的柱狀圖。 Figure 2 depicts a histogram of Day 2 recovery rates for each group according to one embodiment of the present disclosure.
為了使本發明的敘述更加詳盡與完備,下文詳細描述本發明之實施方式與具體實施例;但這並非實施或運用本發明具體實施例的唯一形式。以下所揭示的各實施例,在有益的情形下可相互組合或取代,也可在一實施例中附加其他的實施例,而無須進一步的記載或說明。 In order to make the description of the present invention more detailed and complete, the implementation modes and specific examples of the present invention are described in detail below; but this is not the only form for implementing or using the specific embodiments of the present invention. The various embodiments disclosed below can be combined or replaced with each other when beneficial, and other embodiments can also be added to one embodiment, without further description or illustration.
於本文中所使用之「包含」、「包括」、「具有」及相似詞彙,指明其所記載的特徵、區域、整數、步驟、操作、元件與/或組件,但不排除其它的特徵、區域、整數、步驟、操作、元件、組件,與/或其中之群組。 As used herein, "comprises", "comprises", "has" and similar words indicate the features, regions, integers, steps, operations, elements and/or components described therein, but do not exclude other features and regions , integers, steps, operations, elements, components, and/or groups thereof.
本發明提供一種修復皮膚屏障的組合物包含:靈芝萃取物以及離子調節劑;離子調節劑包含鈣離子、鎂離子、鈉離子、鉀離子及氯離子。 The invention provides a composition for repairing the skin barrier, comprising: ganoderma lucidum extract and an ion regulator; the ion regulator includes calcium ions, magnesium ions, sodium ions, potassium ions and chloride ions.
在一些實施方式中,靈芝萃取物包含葡聚糖和胺基葡萄糖的共聚物,葡聚糖包含α-葡聚糖、β-葡聚糖或其組合,胺基葡萄糖包含N-乙醯葡萄糖胺、N-乙醯胞壁酸或其組合。在一些實施例中,α-葡聚糖包含α-1,4-葡聚糖、α-1,6-葡聚糖或其組合,β-葡聚糖包含β-1,3-D-葡聚糖、β-1,4-D-葡聚糖、β-1,6-D-葡聚糖或其組合。 In some embodiments, the Ganoderma lucidum extract comprises a copolymer of dextran comprising α-glucan, β-glucan or a combination thereof and glucosamine comprising N-acetylglucosamine , N-acetylmuramic acid, or a combination thereof. In some embodiments, the alpha-glucan comprises alpha-1,4-glucan, alpha-1,6-glucan or a combination thereof, the beta-glucan comprises beta-1,3-D-glucan Glycans, beta-1,4-D-glucans, beta-1,6-D-glucans, or combinations thereof.
在一些實施方式中,組合物的總重量以100%計,靈芝萃取物的重量百分比為0.0000072%至0.11%、鈣離子的重量百分比為0.0001244%至0.04998%、鎂離子的重量百分比為0.0000412%至0.03157%、鈉離子的重量百分比為0.0002133%至0.09114%、鉀離子的重量百分比為0.0000875%至0.03301%、及氯離子的重量百分比為0.0004754%至0.16639%。 In some embodiments, the total weight of the composition is based on 100%, the weight percentage of Ganoderma lucidum extract is 0.0000072% to 0.11%, the weight percentage of calcium ion is 0.0001244% to 0.04998%, and the weight percentage of magnesium ion is 0.0000412% to 0.03157%, the weight percentage of sodium ions is 0.0002133% to 0.09114%, the weight percentage of potassium ions is 0.0000875% to 0.03301%, and the weight percentage of chloride ions is 0.0004754% to 0.16639%.
在一實施方式中,靈芝萃取物為靈芝細胞壁萃取物。靈芝包含靈芝屬(Ganoderma)下之真菌,可例如為赤芝(Ganoderma lucidum)或松杉靈芝(Ganoderma Tsugae)等。靈芝萃取物依其纖維尺寸可為微米等級的靈 芝萃取物,或為奈米等級的靈芝萃取物。在一些實施方式中,組合物的總重量以100%計,微米等級的靈芝萃取物的重量百分比可為0.0000072%至0.088%。在一些實施方式中,組合物的總重量以100%計,奈米等級的靈芝萃取物的重量百分比為0.00018%至0.11%。 In one embodiment, the Ganoderma lucidum extract is Ganoderma lucidum cell wall extract. Ganoderma lucidum includes fungi under the genus Ganoderma ( Ganoderma ), such as Ganoderma lucidum or Ganoderma Tsugae . According to the size of the fiber, Ganoderma lucidum extract can be micron scale Ganoderma lucidum extract, or nano scale Ganoderma lucidum extract. In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the micron-sized Ganoderma lucidum extract may be 0.0000072% to 0.088%. In some embodiments, the total weight of the composition is based on 100%, and the weight percentage of the nanoscale Ganoderma lucidum extract is 0.00018% to 0.11%.
在一實施方式中,靈芝萃取物的重量百分比為0.02%、鈣離子的重量百分比為0.0469%、鎂離子的重量百分比為0.02296%、鈉離子的重量百分比為0.08225%、鉀離子的重量百分比為0.0315%、及氯離子的重量百分比為0.16639%。 In one embodiment, the weight percentage of Ganoderma lucidum extract is 0.02%, the weight percentage of calcium ions is 0.0469%, the weight percentage of magnesium ions is 0.02296%, the weight percentage of sodium ions is 0.08225%, and the weight percentage of potassium ions is 0.0315% %, and the percentage by weight of chloride ions is 0.16639%.
在一些實施方式中,所述修復皮膚屏障的組合物係呈液劑、精華液、洗劑、卸妝產品、面膜、擦拭產品、乳液、乳霜、軟膏、或凝膠之形式。 In some embodiments, the composition for repairing the skin barrier is in the form of a liquid, serum, lotion, makeup remover, mask, wipe, lotion, cream, ointment, or gel.
在一些實施方式中,所述修復皮膚屏障的組合物更包含化妝品可接受的載劑,載劑包含溶劑、潤膚劑、保濕劑、乳化劑、增稠劑、抗氧化劑、防腐劑或其組合。 In some embodiments, the composition for repairing the skin barrier further comprises a cosmetically acceptable carrier, and the carrier includes solvents, emollients, moisturizers, emulsifiers, thickeners, antioxidants, preservatives or combinations thereof .
在一實施方式中,溶劑包括,但不限於水。 In one embodiment, the solvent includes, but is not limited to water.
在一些實施方式中,組合物的總重量以100%計,潤膚劑的重量百分比為7%至22%。 In some embodiments, the total weight of the composition is 100%, and the emollient is present in an amount of 7% to 22% by weight.
在一些實施方式中,組合物的總重量以100%計,潤膚劑的重量百分比為2%至30%。在一實施方式中,潤膚劑包括,但不限於辛酸甘油三酯(Caprylic Triglyceride)、癸酸甘油三酯(Capric Triglyceride)、異壬酸異壬酯(Isononyl Isononanoate)、聚丁烯(Polybutene)、環五聚二甲基矽氧烷(Cyclopentasiloxane)、十二碳烯(Dodecene)、或其組合。 In some embodiments, the total weight of the composition is 100%, and the emollient is present in an amount of 2% to 30% by weight. In one embodiment, emollients include, but are not limited to, Caprylic Triglyceride, Capric Triglyceride, Isononyl Isononanoate Isononanoate), Polybutene, Cyclopentasiloxane, Dodecene, or a combination thereof.
在一些實施方式中,組合物的總重量以100%計,保濕劑的重量百分比為4%至12%。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the moisturizer is 4% to 12%.
在一些實施方式中,組合物的總重量以100%計,保濕劑的重量百分比為0.1%至20%。在一實施方式中,保濕劑包括,但不限於甘油(Glycerin)、1,2-己二醇(1,2-Hexanediol)、甘露糖醇(Mannitol)、1,3-丙二醇(Propanediol)、乙基己基甘油(Ethylhexylglycerin)或其組合。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the moisturizing agent is 0.1% to 20%. In one embodiment, humectants include, but are not limited to, glycerin (Glycerin), 1,2-hexanediol (1,2-Hexanediol), mannitol (Mannitol), 1,3-propanediol (Propanediol), ethanol Ethylhexylglycerin or combinations thereof.
在一些實施方式中,組合物的總重量以100%計,乳化劑的重量百分比為2%至6.5%。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the emulsifier is 2% to 6.5%.
在一些實施方式中,組合物的總重量以100%計,乳化劑的重量百分比為0.1%至10%。在一實施方式中,乳化劑包括,但不限於月桂基聚甲基矽氧烷(例如,月桂基PEG/PPG-18/18聚甲基矽氧烷Lauryl PEG/PPG-18/18 Methicone)、異硬脂醇(Isostearyl Alcohol)、月桂醯乳醯乳酸鈉(Sodium Lauroyl Lactylate)、或其組合。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the emulsifier is 0.1% to 10%. In one embodiment, emulsifiers include, but are not limited to, lauryl methicone (e.g., lauryl PEG/PPG-18/18 methicone, Lauryl PEG/PPG-18/18 Methicone), Isostearyl Alcohol, Sodium Lauroyl Lactylate, or a combination thereof.
在一些實施方式中,組合物的總重量以100%計,增稠劑的重量百分比為0.3%至1%。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the thickener is 0.3% to 1%.
在一些實施方式中,組合物的總重量以100%計,增稠劑的重量百分比為0.1%至5%。在一實施方式中,增 稠劑包括,但不限於羥乙基纖維素(Hydroxyethylcellulose)、聚二甲基矽氧烷交聯聚合物(Dimethicone Crosspolymer)、黃原膠(Xanthan Gum)、卡波姆(Carbomer)、或其組合。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the thickener is 0.1% to 5%. In one embodiment, increasing Thickeners include, but are not limited to, Hydroxyethylcellulose, Dimethicone Crosspolymer, Xanthan Gum, Carbomer, or combinations thereof .
在一些實施方式中,組合物的總重量以100%計,抗氧化劑的重量百分比為0.2%至0.8%。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the antioxidant is 0.2% to 0.8%.
在一些實施方式中,組合物的總重量以100%計,抗氧化劑的重量百分比為0.01%至5%。在一實施方式中,抗氧化劑包括,但不限於對羥基苯乙酮(Hydroxyacetophenone)或生育酚乙酸酯(Tocopheryl Acetate)。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the antioxidant is 0.01% to 5%. In one embodiment, antioxidants include, but are not limited to, Hydroxyacetophenone or Tocopheryl Acetate.
在一些實施方式中,組合物的總重量以100%計,防腐劑的重量百分比為0.0004%至0.002%。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the preservative is 0.0004% to 0.002%.
在一些實施方式中,組合物的總重量以100%計,防腐劑的重量百分比為0.0004%至5%。在一實施方式中,防腐劑包括,但不限於苯氧乙醇(Phenoxyethanol)。 In some embodiments, based on 100% of the total weight of the composition, the weight percentage of the preservative is 0.0004% to 5%. In one embodiment, preservatives include, but are not limited to, phenoxyethanol (Phenoxyethanol).
在一些實施方式中,所述修復皮膚屏障的組合物更包含一藥學上可接受的載劑。 In some embodiments, the composition for repairing the skin barrier further includes a pharmaceutically acceptable carrier.
本發明另提供一種修復皮膚屏障的之組合物的用途,係用於製備治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀的製劑。 The present invention also provides the use of a composition for repairing the skin barrier, which is used for preparing preparations for treating skin diseases or improving skin discomfort or abnormal symptoms caused by diseases.
在一些實施方式中,皮膚病包括異位性皮膚炎、脂漏性皮膚炎、接觸性皮膚炎、紅斑性狼瘡、扁平苔癬、蕁麻疹、角化病、痤瘡、牛皮癬、或魚鱗病。 In some embodiments, the skin disease comprises atopic dermatitis, seborrheic dermatitis, contact dermatitis, lupus erythematosus, lichen planus, urticaria, keratosis, acne, psoriasis, or ichthyosis.
本發明另提供一種修復皮膚屏障的之組合物的用途,係用於製備治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀的製劑,其中投與該組合物為每日至少一次。在一些實施方式中,投與該組合物為每日一次、兩次、三次或四次。 The present invention also provides the use of a composition for repairing the skin barrier, which is used to prepare preparations for treating skin diseases or improving skin discomfort or abnormal symptoms caused by diseases, wherein the composition is administered at least once a day. In some embodiments, the composition is administered once, twice, three times, or four times daily.
在一些實施方式中,皮膚病或該疾病所引起之皮膚不適或異常症狀於施予該組合物兩天時,其恢復率相較於對照組增加10%或更多。在一實施方式中,其恢復率相較於對照組增加10~50%,例如,11%、12%、13%、15%、20%、25%、30%或40%。 In some embodiments, when the skin disease or the skin discomfort or abnormal symptoms caused by the disease is administered for two days, the recovery rate is increased by 10% or more compared with the control group. In one embodiment, the recovery rate is increased by 10-50%, for example, 11%, 12%, 13%, 15%, 20%, 25%, 30% or 40% compared with the control group.
在一具體實施例中,修復皮膚屏障的組合物按下表1所列成分比例調製: In a specific embodiment, the composition for repairing the skin barrier is prepared according to the ratio of ingredients listed in Table 1:
在一些實施方式中,修復皮膚屏障的組合物更包含脂質,組合物的總重量以100%計,脂質的重量百分比為0.001%至40%,在另一些實施方式中,脂質的重量百分比為
0.001%至15%。在一實施方式中,脂質包含神經醯胺、甘油酯、膽固醇、游離脂肪酸或其組合。在一些實施例中,神經醯胺包含神經醯胺1、神經醯胺2、神經醯胺3、神經醯胺4、神經醯胺5、神經醯胺6、神經醯胺7、神經醯胺8、神經醯胺9、或其組合。在一實施例中,神經醯胺包含神經醯胺1、神經醯胺3、神經醯胺6II。
In some embodiments, the composition for repairing the skin barrier further comprises lipid, the total weight of the composition is based on 100%, and the weight percentage of lipid is 0.001% to 40%, and in other embodiments, the weight percentage of lipid is
0.001% to 15%. In one embodiment, the lipid comprises ceramides, glycerides, cholesterol, free fatty acids, or combinations thereof. In some embodiments, the ceramide comprises ceramide 1, ceramide 2, ceramide 3, ceramide 4,
神經醯胺是人體皮膚角質層細胞間基質的主要成分。角質層細胞間基質主要係由脂質構成,即「磚與泥」結構中的泥,脂質由約50%的神經醯胺、約25%的膽固醇和約15%的游離脂肪酸組成,神經醯胺、膽固醇和游離脂肪酸一起,產生一個不透水的保護性結構,以防止過多的水分蒸發,同時也阻止微生物及外在刺激原的進入。 Ceramide is the main component of the intercellular matrix of the stratum corneum of human skin. The intercellular matrix of the stratum corneum is mainly composed of lipids, that is, the mud in the "brick and mud" structure. Lipids are composed of about 50% ceramide, about 25% cholesterol and about 15% free fatty acids. Ceramide, Cholesterol and free fatty acids together create an impermeable protective structure that prevents excess water from evaporating and also prevents the entry of microorganisms and external irritants.
在另一具體實施例中,修復皮膚屏障的組合物按下表2所列成分比例調製: In another specific embodiment, the composition for repairing the skin barrier is prepared according to the ratio of ingredients listed in Table 2:
本發明之修復皮膚屏障的組合物,可用於治療皮膚病或是改善疾病所引起之皮膚不適或異常症狀。皮膚病可例如為異位性皮膚炎、脂漏性皮膚炎、接觸性皮膚炎、紅斑性狼瘡、扁平苔癬、蕁麻疹、角化病、痤瘡、牛皮癬、或魚鱗病。疾病所引起之皮膚不適或異常症狀可例如為皮膚病或其他疾病所引起的皮膚乾燥、搔癢、脫皮、紅腫刺痛等發炎反應。 The composition for repairing the skin barrier of the present invention can be used to treat skin diseases or improve skin discomfort or abnormal symptoms caused by diseases. The skin disease can be, for example, atopic dermatitis, seborrheic dermatitis, contact dermatitis, lupus erythematosus, lichen planus, urticaria, keratosis, acne, psoriasis, or ichthyosis. Skin discomfort or abnormal symptoms caused by diseases can be, for example, skin dryness, itching, peeling, redness, swelling and tingling caused by skin diseases or other diseases.
洗腎透析患者常會全身發癢,稱之為「尿毒性搔癢症(uremic pruritus)」。尿毒性搔癢症的症狀通常是全身性的,最常在背部(50%)、臉(30%)、廔管側上肢(10%)和下肢(5%)。尿毒性搔癢症可能的原因在於:(1)副甲狀腺機能亢進症;(2)雙價離子代謝的改變,如血鈣或血鎂過高,雙價陽離子可能大量沈積於真皮層成為刺激源;(3)中樞性神經源性的搔癢,可能是來自鴉片類的神經系統;(4)週邊神經病變,從尿毒症患者的表皮切片觀察出有神經纖維增加的現象,可能與皮膚搔癢有關;(5)皮脂腺分泌異常或汗液分泌減少,造成皮膚乾燥;(6)維生素A過多症,使皮膚變得更乾燥和更易脫皮;(7)肥大細胞增生或其易受激發而釋放組織胺。在一些實施方式中,本發明之修復皮膚屏障的組合物,可用於改善尿毒性搔癢症所引起之皮膚不適或異常症狀。 Kidney dialysis patients often experience itching all over the body, which is called "uremic pruritus". Symptoms of uremic pruritus are usually generalized, most often in the back (50%), face (30%), ductal upper extremities (10%), and lower extremities (5%). The possible causes of uremic pruritus are: (1) hyperparathyroidism; (2) changes in the metabolism of divalent ions, such as high blood calcium or blood magnesium, and a large amount of divalent cations may be deposited in the dermis as a source of stimulation; (3) CNS-derived itching, which may be from the nervous system of opioids; (4) Peripheral neuropathy, the phenomenon of increased nerve fibers observed in epidermal sections of patients with uremia, which may be related to skin itching; ( 5) Abnormal secretion of sebaceous glands or decreased sweat secretion, resulting in dry skin; (6) hypervitaminosis A, which makes the skin drier and easier to peel; (7) mast cells proliferate or are easily stimulated to release histamine. In some embodiments, the composition for repairing the skin barrier of the present invention can be used to improve skin discomfort or abnormal symptoms caused by uremic pruritus.
以下實驗例將說明本發明實施例之修復皮膚屏障的組合物對於修復皮膚屏障之功效。 The following experimental example will illustrate the effect of the composition for repairing the skin barrier of the embodiment of the present invention on repairing the skin barrier.
修復皮膚屏障實驗 Repair skin barrier experiment
取約7周大的裸鼠(Nude mice)數隻,體重落在20±2克並隨意進食與飲水。實驗分為1組對照組與3組實驗組總共4組。將裸鼠麻醉後以脊椎為中心,於左右大腿分別以2支無菌棉棒沾生理食鹽水來回擦拭,每支棉棒來回擦拭5次,然後以乾的無菌棉棒1支來回擦拭3次等待乾燥。接著,於兩側大腿畫出1.5公分* 1.5公分的四角方框,測量經皮水分散失量(Transepidermal water loss,TEWL),並紀錄為基礎值。接著,於兩側大腿的四角方框內,以約3公分* 2.5公分大小的膠帶撕剝10-15次,每次停留10秒。接著量測經皮水分散失量。最後,依各組別分別投藥,固定面積4.5公分* 2.5公分來回塗抹依表3配方配製的水凝膠3分鐘至乾澀無法再抹為止。之後每天皆重複清潔、乾燥、測量與投藥的過程。因此,共紀錄第0天(撕前基礎值)、第0天(撕後)、第1天、第2天與第3天的經皮水分散失量。 Take a few nude mice (Nude mice) about 7 weeks old, with a body weight of 20±2 grams, and eat and drink freely. The experiment was divided into 1 control group and 3 experimental groups, a total of 4 groups. After the nude mice were anesthetized, the spine was centered, and the left and right thighs were wiped back and forth with 2 sterile cotton swabs dipped in saline. Each cotton swab was wiped back and forth 5 times, and then a dry sterile cotton swab was wiped back and forth 3 times and waited. dry. Then, draw a square of 1.5 cm * 1.5 cm on both sides of the thigh, measure the transepidermal water loss (TEWL), and record it as the basic value. Then, in the four corners of the thighs on both sides, peel off the tape with a size of about 3 cm * 2.5 cm 10-15 times, and stay for 10 seconds each time. Then measure the transdermal water loss. Finally, administer medicines according to each group, and apply the hydrogel prepared according to the formula in Table 3 back and forth on a fixed area of 4.5 cm * 2.5 cm for 3 minutes until it becomes dry and can no longer be applied. Afterwards, the process of cleaning, drying, measuring and dosing was repeated every day. Therefore, the transdermal water loss on day 0 (basic value before tearing), day 0 (after tearing), day 1, day 2, and day 3 was recorded.
對照組與實驗組A-C的配方如下表3,其中離子調節劑中鈣離子、鎂離子、鈉離子、鉀離子及氯離子含量如表1所示。 The formulations of the control group and the experimental groups A-C are shown in Table 3, and the contents of calcium ions, magnesium ions, sodium ions, potassium ions and chloride ions in the ion regulator are shown in Table 1.
實驗結果請參閱第1圖,在第2天時,各組別扣除基礎值後的平均經皮水分散失量分別為對照組23.70g/h/m2、實驗組A 21.09g/h/m2、實驗組B 18.80g/h/m2及實驗組C 14.26g/h/m2。由此可知,相較於單獨使用離子調節劑(實驗組A)與單獨使用靈芝萃取物(實驗組B)而言,同時使用離子調節劑與靈芝萃取物的實驗組C,其經皮水分散失量的減少程度更為顯著。換言之,皮膚屏障的修復效果更佳。值得留意的是,相較於對照組,使用本發明組合物之皮膚經皮水分散失量的減少量(9.44),大於單獨使用靈芝萃取物與離子調節劑的經皮水分散失量減少量的總和(2.61+4.90),可見靈芝萃取物與離子調節劑具有協同效果(synergistic effect)。 Please refer to Figure 1 for the experimental results. On the second day, the average transdermal water loss of each group after deducting the base value was 23.70g/h/m 2 for the control group and 21.09g/h/m 2 for the experimental group A 18.80g/h/m 2 for experimental group B and 14.26g/h/m 2 for experimental group C. It can be seen that compared with the use of ion regulators alone (experimental group A) and the use of ganoderma lucidum extract alone (experimental group B), the experimental group C that uses ion regulators and ganoderma lucidum extracts at the same time has less transdermal water loss. The reduction in volume is more pronounced. In other words, the repair effect of the skin barrier is better. It is worth noting that, compared with the control group, the reduction in skin transdermal water loss (9.44) using the composition of the present invention is greater than the sum of the reductions in transdermal water loss of using Ganoderma lucidum extract and ion regulator alone (2.61+4.90), it can be seen that Ganoderma lucidum extract and ion regulator have a synergistic effect.
再者,計算在第2天各組的恢復率,恢復率計算方式為{1-[(第2天TEWL平均-基礎值平均)/(第0天撕後 TEWL平均-基礎值平均)]}* 100。如第2圖所示,對照組恢復率為54.3%、實驗組A恢復率為50%、實驗組B恢復率為55.1%及實驗組C恢復率為66.7%。換言之,實驗組C恢復率相較於對照組增加12.4%。這可能是由於單獨使用靈芝萃取物雖可促進角質細胞增生,但離子調節劑中的特定離子組合及比例可調節表皮層中的鈣離子濃度梯度呈倒梯形分布,加速皮膚角質細胞增生,以達成修復皮膚屏障的功效。其次,鈣離子亦可幫助角質細胞分化。 Furthermore, calculate the recovery rate of each group on the second day, and the calculation method of the recovery rate is {1-[(the average TEWL on the second day-the average value of the base value)/(the tear after tearing on the 0th day TEWL average - base value average)]} * 100. As shown in Figure 2, the recovery rate of the control group was 54.3%, the recovery rate of the experimental group A was 50%, the recovery rate of the experimental group B was 55.1%, and the recovery rate of the experimental group C was 66.7%. In other words, the recovery rate of C in the experimental group increased by 12.4% compared with that in the control group. This may be due to the fact that Ganoderma lucidum extract alone can promote keratinocyte proliferation, but the specific ion combination and ratio in the ion regulator can adjust the calcium ion concentration gradient in the epidermis to present an inverted trapezoidal distribution, accelerating skin keratinocyte proliferation, in order to achieve The effect of repairing the skin barrier. Secondly, calcium ions can also help keratinocytes differentiate.
本發明在組合物中,由組合物中之靈芝萃取物促進細胞再生,加速皮膚角質細胞增生。再利用離子調節劑中特定比例的離子組合,回復皮膚表皮層中的鈣離子濃度梯度的倒梯形分布,以提供適合角質細胞生長的環境。最後,特定比例的離子組合可持續維持皮膚屏障層的鈣離子濃度梯度的倒梯形分布,維持新生皮膚屏障之功能。藉由本發明組合物修復皮膚屏障,可防止外在刺激原入侵皮膚及皮膚水分流失,避免皮膚受到外在刺激後導致發炎反應而有紅腫熱刺的不舒適感。其次,本發明組合物亦可用於病理狀態下的皮膚,藉由修復皮膚屏障而治療或改善皮膚不適或異常症狀,包含洗腎透析病患的皮膚搔癢症狀。 In the composition of the present invention, the ganoderma lucidum extract in the composition promotes cell regeneration and accelerates skin keratinocyte proliferation. Then use the ion combination in a specific ratio in the ion regulator to restore the inverted trapezoidal distribution of the calcium ion concentration gradient in the epidermal layer of the skin to provide an environment suitable for the growth of keratinocytes. Finally, the combination of ions in a specific ratio can sustainably maintain the inverted trapezoidal distribution of the calcium ion concentration gradient of the skin barrier layer and maintain the function of the new skin barrier. Repairing the skin barrier by the composition of the present invention can prevent external stimuli from invading the skin and losing water in the skin, and prevent the skin from being irritated by external stimuli and causing discomfort such as redness, swelling, and heat. Secondly, the composition of the present invention can also be used on skin under pathological conditions to treat or improve skin discomfort or abnormal symptoms by repairing the skin barrier, including skin itching symptoms of kidney dialysis patients.
雖然本發明已以實施方式揭露如上,然其並非用以限定本發明,任何熟習此技藝者,在不脫離本發明之精神和範圍內,當可作各種之更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 Although the present invention has been disclosed above in terms of implementation, it is not intended to limit the present invention. Anyone skilled in this art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection of the present invention The scope shall be defined by the appended patent application scope.
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW108104301 | 2019-02-01 | ||
TW108104301 | 2019-02-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202029975A TW202029975A (en) | 2020-08-16 |
TWI801711B true TWI801711B (en) | 2023-05-11 |
Family
ID=71910430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109103251A TWI801711B (en) | 2019-02-01 | 2020-02-03 | Composition for restoring the skin barrier and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111514173A (en) |
TW (1) | TWI801711B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114173751B (en) * | 2021-11-03 | 2023-03-07 | 珠海德贡实业有限公司 | Barrier repairing composition, skin care product, preparation method of skin care product and application of skin care product in preparation of wet tissue |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006001837A (en) * | 2004-06-15 | 2006-01-05 | Nonogawa Shoji Kk | Opioid receptor damage inhibitor |
CN101146508A (en) * | 2005-02-11 | 2008-03-19 | 通用名制药公司 | Cosmetic and cosmeceutical compositions for restoration of skin barrier function |
JP5860577B2 (en) * | 2008-04-17 | 2016-02-16 | 丸善製薬株式会社 | Claudin production promoter and occludin production promoter |
CN103585096B (en) * | 2013-11-12 | 2016-05-25 | 六安市丹皇生物科技有限责任公司 | A kind of face of living essence and preparation method thereof that compacts |
CN107095828B (en) * | 2017-07-03 | 2020-08-11 | 四川省中医药科学院 | Daily chemical product composition with skin barrier repair function and preparation method and application thereof |
-
2020
- 2020-02-03 CN CN202010078498.9A patent/CN111514173A/en active Pending
- 2020-02-03 TW TW109103251A patent/TWI801711B/en active
Also Published As
Publication number | Publication date |
---|---|
TW202029975A (en) | 2020-08-16 |
CN111514173A (en) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11234921B2 (en) | Moisturizing compositions and uses thereof | |
JP6227856B2 (en) | Composition and method for skin care | |
US11285093B2 (en) | Cosmetic uses of swertiamarin | |
CN111265468A (en) | Skin double-barrier repair composition and application thereof | |
CH705713B1 (en) | Dermocosmetic composition with filling action, useful e.g. for smoothing wrinkles or furrows in epidermis by topical application, comprises mixture containing hyaluronic acids, which includes e.g. hyaluronic acid crosspolymer, and carrier | |
CN112294666B (en) | Silica gel eye cream with permeation promoting function | |
CN111973508A (en) | Anti-aging composition capable of relieving and moisturizing | |
JP5891651B2 (en) | Skin preparation for normalization of stratum corneum cell differentiation | |
EP2763686A1 (en) | Composition for the treatment of skin lesions | |
TWI801711B (en) | Composition for restoring the skin barrier and use thereof | |
CN108721154B (en) | Skin care product for skin moisturizing and barrier repair and preparation method thereof | |
US20080260675A1 (en) | Depolymerized Scleroglucan for Regulating and Improving the Moisture Content of the Skin | |
US20100104673A1 (en) | Methods and Compositions for Treatment of Skin Conditions | |
CN115024997B (en) | Cosmetic composition with skin aging resisting effect | |
CN111973471A (en) | Cosmetic composition | |
CN116407486A (en) | Active composition, cosmetic composition, application of active composition, repairing essence and preparation method of repairing essence | |
KR20240082385A (en) | Whitening composition and method of use | |
EP3706714B1 (en) | N-acetylcysteine and urea-based formulation for the treatment of dermatological disorders | |
CN115282105A (en) | Infant Tong Hufu composition and preparation method thereof | |
CN109937029A (en) | The combination and method of anti-aging sign | |
Weber et al. | Hand and foot moisturizers | |
US20220110967A1 (en) | Methods and compositions for therapeutic skin treatments in dermatological procedures affecting skin's barrier | |
DE102022202547A1 (en) | Topically applicable preparation to improve the condition of the skin | |
CN112807372A (en) | Cream capable of treating chilblain and skin chap | |
CN116747147A (en) | Azelaic acid micro-nano crystal suspension for targeted acne removal and application thereof |